India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
EBITDA before special items falls 1.3 percent to € 4.41 billion
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Subscribe To Our Newsletter & Stay Updated
